Treatment with auraptene (3–30 μM, 8–24 h) downregulates mTOR-ribosomal S6 kinase (S6K) signaling, reduces lipid synthesis, and inhibits AR expression, collectively impeding PCa cell proliferation and survival (Akasaka et al., 2023). The gene discussed is AR; the disease is posterior cortical atrophy.